A new milestone in the retatrutide clinical trial results landscape quietly appeared on ClinicalTrials.gov: the study titled A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia (NCT06982846) has moved from active, non-recruiting status to completed, with a primary completion date of May 4, 2026. For the thousands of people following retatrutide's path toward potential FDA approval, this update carries meaningful clinical significance.
To understand why, some context helps. Retatrutide — commonly referred to as reta in patient communities — is a once-weekly subcutaneous injection developed by Eli Lilly and Company. It is a triple hormone receptor agonist, acting simultaneously on GLP-1, GIP, and glucagon receptors. This tri-receptor mechanism, sometimes called "triple G" in patient forums, is what distinguishes retatrutide from earlier generation agents and is responsible for its remarkable efficacy signal across both Phase 2 and Phase 3 trials.
The completed trial focused specifically on how people with type 2 diabetes respond to hypoglycemia while on retatrutide. This is a critical safety question. When a drug activates glucagon receptors — as retatrutide does — it raises a reasonable clinical concern: could that glucagon activity blunt the normal hormonal counter-regulatory response to low blood sugar? Answering this question rigorously, in a controlled trial setting, is a prerequisite for any regulatory submission that includes a type 2 diabetes population. The fact that this study has now completed its primary data collection marks a tangible step forward in retatrutide's regulatory dossier. Full details and results from this specific trial have not yet been publicly reported; the information above reflects only what is documented at ClinicalTrials.gov (NCT06982846).
The hypoglycemia counter-regulation study (NCT06982846) has completed but has not yet published results, so it would be premature to draw efficacy or safety conclusions from it specifically. What the clinical community does have, however, is a robust and already-published set of retatrutide data from Phase 2 and the headline Phase 3 TRIUMPH-4 trial — and those numbers are striking.
In the Phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023; NCT04881760), 338 adults with obesity received retatrutide or placebo for 48 weeks. At the highest doses, results were unprecedented for a pharmacological agent at that stage of development:
Then came TRIUMPH-4. In December 2025, Eli Lilly announced Phase 3 results showing a mean weight loss of 28.7% over 68 weeks at the 12mg dose — the highest mean weight reduction ever reported in a Phase 3 obesity trial. For context, here is how retatrutide compares to currently approved agents at their highest studied doses:
| Drug | Mechanism | Trial | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | GLP-1 / GIP agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | GLP-1 / GIP / Glucagon agonist | TRIUMPH-4 | 68 weeks | 28.7% |
The Phase 2 data also showed retatrutide's effects on what many patients describe as "food noise" — the persistent mental preoccupation with food — appeared potent. While formal food craving scales were not the primary endpoint, the dramatic weight outcomes, even at 24 weeks, suggest meaningful appetite regulation across the dose range. Adverse events were consistent with the GLP-1 drug class: nausea, diarrhea, and vomiting were the most common, were dose-dependent, and peaked during the titration phase. Dysesthesia (abnormal skin sensations) was observed at higher rates with the 12mg dose — 20.9% in TRIUMPH-4 versus 0.7% with placebo — and warrants ongoing attention as the drug moves through the regulatory process.
Completion of the hypoglycemia counter-regulation study is one piece of a larger regulatory puzzle. Before the FDA can approve retatrutide, Eli Lilly must compile a comprehensive New Drug Application (NDA) that includes safety, efficacy, and mechanistic data across all intended patient populations. Studies examining how the drug interacts with low blood sugar events are essential when glucagon receptor agonism is part of a drug's mechanism — the FDA will want evidence that the body's natural protective response to hypoglycemia remains intact.
As of April 2026, Lilly has not yet filed an NDA for retatrutide, and no FDA approval timeline has been publicly confirmed. The peer-reviewed Phase 3 publication from TRIUMPH-4 is also still pending. These are normal, expected steps in the regulatory timeline — not signals of setback. Each completed study adds to the evidentiary package that will ultimately support or shape any regulatory filing.
There is no confirmed approval date, and it would be clinically irresponsible to speculate with false precision. What can be said is that the overall regulatory trajectory is moving forward. Phase 3 has produced results. A hypoglycemia safety study has completed. The efficacy signal — 28.7% mean weight loss in TRIUMPH-4 — is strong enough to generate serious regulatory and commercial attention.
The TRIUMPH program encompasses multiple trials evaluating retatrutide across different populations, including individuals with type 2 diabetes. As each of these studies completes and data are compiled, the NDA dossier takes shape. The timeline from NDA submission to FDA decision typically runs six to twelve months under standard review, though priority review designations can accelerate that window. Until an NDA is submitted and reviewed, retatrutide remains an investigational compound — not an approved therapy.
For patients who have struggled with obesity despite diet, exercise, and existing medications, the science emerging around retatrutide as a triple agonist is genuinely exciting. The question is not whether it works — the clinical data are compelling — but when it will be accessible through legitimate, approved channels.
If retatrutide is something worth watching, the glp3md waitlist exists for exactly that purpose. Joining the waitlist at glp3md.com means receiving updates as new trial data are published, as regulatory milestones are reached, and as the approval landscape evolves. Joining the waitlist does not guarantee access to medication, a prescription, or any form of treatment — retatrutide is not FDA-approved, and no promises are made about future availability. It is simply the most informed place to stay current while this remarkable drug completes its journey through the regulatory process.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.